The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR): Thoracic Oncology Research Group (TORG) 0911.
Yoshiro Nakahara
Honoraria - Chugai Pharma
Yukio Hosomi
Honoraria - Chugai Pharma
Kazuhiko Yamada
No relevant relationships to disclose
Hiroaki Okamoto
No relevant relationships to disclose
Terufumi Kato
Honoraria - Chugai Pharma
Yuko Komase
No relevant relationships to disclose
Masanori Nishikawa
No relevant relationships to disclose
Satoshi Morita
Honoraria - Chugai Pharma
Hideo Kunitoh
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca
Koshiro Watanabe
No relevant relationships to disclose